Six years ago, the top executives at NPS Pharmaceuticals staked out a new path. They wanted the company, founded in 1986, to become a leader in developing therapies for people with rare diseases. The early results are promising. In early 2013, NPS introduced Gattex to treat short bowel syndrome, a rare and disabling condition that prevents people from absorbing adequate nutrients through the intestinal tract. Next in the pipeline is Natpara, a treatment for adult hypoparathyroidism, a disease interrupting the body's ability to regulate calcium and phosphorus.